<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33408178</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>24</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Coxsackievirus A5 Vaccine Candidates in an Actively Immunized Mouse Model.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e01743-20</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01743-20</ELocationID><Abstract><AbstractText>Coxsackievirus A5 (CV-A5) has recently emerged as a main hand, foot, and mouth disease (HFMD) pathogen. Following a large-scale vaccination campaign against enterovirus 71 (EV-71) in China, the number of HFMD-associated cases with EV-71 was reduced, especially severe and fatal cases. However, the total number of HFMD cases remains high, as HFMD is also caused by other enterovirus serotypes. A multivalent HFMD vaccine containing 4 or 6 antigens of enterovirus serotypes is urgently needed. A formaldehyde-inactivated CV-A5 vaccine derived from Vero cells was used to inoculate newborn Kunming mice on days 3 and 10. The mice were challenged on day 14 with a mouse-adapted CV-A5 strain at a dose that was lethal for 14-day-old suckling mice. Within 14 days postchallenge, groups of mice immunized with three formulations, empty particles (EPs), full particles (FPs), and a mixture of the EP and FP vaccine candidates, all survived, while 100% of the mock-immunized mice died. Neutralizing antibodies (NtAbs) were detected in the sera of immunized mice, and the NtAb levels were correlated with the survival rate of the challenged mice. The virus loads in organs were reduced, and pathological changes and viral protein expression were weak or not observed in the immunized mice compared with those in alum-inoculated control mice. Another interesting finding was the identification of CV-A5 dense particles (DPs), facilitating morphogenesis study. These results demonstrated that the Vero cell-adapted CV-A5 strain is a promising vaccine candidate and could be used as a multivalent HFMD vaccine component in the future.<b>IMPORTANCE</b> The vaccine candidate strain CV-A5 was produced with a high infectivity titer and a high viral particle yield. Three particle forms, empty particles (EPs), full particles (FPs), and dense particles (DPs), were obtained and characterized after purification. The immunogenicities of EP, FP, and the EP and FP mixture were evaluated in mice. Mouse-adapted CV-A5 was generated as a challenge strain to infect 14-day-old mice. An active immunization challenge mouse model was established to evaluate the efficacy of the inactivated vaccine candidate. This animal model mimics vaccination, similar to immune responses of the vaccinated. The animal model also tests protective efficacy in response to the vaccine against the disease. This work is important for the preparation of multivalent vaccines against HFMD caused by different emerging strains.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 American Society for Microbiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Wei-Ping</ForeName><Initials>WP</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products, Co. Ltd., Jiangxia District, Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products, Co. Ltd., Jiangxia District, Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiao-Yu</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products, Co. Ltd., Jiangxia District, Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products, Co. Ltd., Jiangxia District, Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Zhen-Ni</ForeName><Initials>ZN</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products, Co. Ltd., Jiangxia District, Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mai</LastName><ForeName>Jian-Yi</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products, Co. Ltd., Jiangxia District, Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Sha-Sha</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products, Co. Ltd., Jiangxia District, Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yu-Ting</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products, Co. Ltd., Jiangxia District, Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Sheng-Li</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products, Co. Ltd., Jiangxia District, Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ze-Jun</ForeName><Initials>ZJ</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products, Co. Ltd., Jiangxia District, Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Shuo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0916-053X</Identifier><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products, Co. Ltd., Jiangxia District, Wuhan, People's Republic of China shenshuo1@sinopharm.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CV-A5 vaccine</Keyword><Keyword MajorTopicYN="N">active immunization</Keyword><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">mouse model</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33408178</ArticleId><ArticleId IdType="pmc">PMC8094937</ArticleId><ArticleId IdType="doi">10.1128/JVI.01743-20</ArticleId><ArticleId IdType="pii">JVI.01743-20</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hu YF, Yang F, Du J, Dong J, Zhang T, Wu ZQ, Xue Y, Jin Q. 2011. Complete genome analysis of coxsackievirus A2, A4, A5, and A10 strains isolated from hand, foot, and mouth disease patients in China revealing frequent recombination of human enterovirus A. J Clin Microbiol 49:2426&#x2013;2434. doi:10.1128/JCM.00007-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00007-11</ArticleId><ArticleId IdType="pmc">PMC3147834</ArticleId><ArticleId IdType="pubmed">21543560</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. 2010. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10:778&#x2013;790. doi:10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang FK, Lu J, Wu J, Wang ZJ, Ji YQ, Zheng XL, Shen S. 2016. Immunogenicity of full and empty particles of coxsackievirus A16. Chin J Biol 28:1132&#x2013;1137. doi:10.13200/j.cnki.cjb.001133.</Citation><ArticleIdList><ArticleId IdType="doi">10.13200/j.cnki.cjb.001133</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulli T, Koskimies P, Hyypi&#xe4; T. 1995. Molecular comparison of coxsackie A virus serotypes. Virology 212:30&#x2013;38. doi:10.1006/viro.1995.1450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1995.1450</ArticleId><ArticleId IdType="pubmed">7676647</ArticleId></ArticleIdList></Reference><Reference><Citation>Flewett TH, Warin RP, Clarke SK. 1963. &#x201c;Hand, foot, and mouth disease&#x201d; associated with Coxsackie A5 virus. J Clin Pathol 16:53&#x2013;55. doi:10.1136/jcp.16.1.53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jcp.16.1.53</ArticleId><ArticleId IdType="pmc">PMC480485</ArticleId><ArticleId IdType="pubmed">13945538</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavate O, Avram G, Pavlov E, Burlea-Iriciuc A, Ivan A, Cotor F. 1984. Coxsackie A virus-associated herpetiform angina. Virologie 35:49&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">6324449</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe2;rlean L, Avram G, Pavlov E, Cotor F. 1994. Investigation of five cases of vesicular enteroviral stomatitis with exanthema induced by coxsackie A5 virus. Rev Roum Virol 45:3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7756162</ArticleId></ArticleIdList></Reference><Reference><Citation>Davia JL, Bel PH, Ninet VZ, Bracho MA, Gonz&#xe1;lez-Candelas F, Salazar A, Gobernado M, Bosch IF. 2011. Onychomadesis outbreak in Valencia, Spain associated with hand, foot, and mouth disease caused by enteroviruses. Pediatr Dermatol 28:1&#x2013;5. doi:10.1111/j.1525-1470.2010.01161.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1470.2010.01161.x</ArticleId><ArticleId IdType="pubmed">20553401</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham NTK, Thongprachum A, Trinh QD, Okitsu S, Komine-Aizawa S, Shimizu H, Hayakawa S, Ushijima H. 2018. Detection and genetic characterization of enterovirus strains circulating among children with acute gastroenteritis in Japan during 2014&#x2013;2016. Infect Genet Evol 61:16&#x2013;19. doi:10.1016/j.meegid.2018.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2018.03.009</ArticleId><ArticleId IdType="pubmed">29540319</ArticleId></ArticleIdList></Reference><Reference><Citation>Boros &#xc1;, Pankovics P, K&#x151;m&#xed;ves S, Liptai Z, Dobner S, Ujhelyi E, V&#xe1;rallyay G, Zsidegh P, Bolba N, Reuter G. 2017. Co-infection with coxsackievirus A5 and norovirus GII.4 could have been the trigger of the first episode of severe acute encephalopathy in a six-year-old child with the intermittent form of maple syrup urine disease (MSUD). Arch Virol 162:1757&#x2013;1763. doi:10.1007/s00705-017-3299-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-017-3299-z</ArticleId><ArticleId IdType="pubmed">28243803</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji YL, Wang YW. 2012. Analysis on the characteristics of severe hand foot and mouth disease cases and molecular typing of the causative agent. Modern Prev Med
39:2817&#x2013;2819. https://doi.org/CNKI:SUN:XDYF.0.2012-11-071.</Citation></Reference><Reference><Citation>D'Angelo A, Ferrante P, Barbi Guidotti M, Provera F. 1983. Influenza B-associated Reye syndrome: report of a case with isolation of a coxsackie A5 virus from CSF. Ital J Neurol Sci 4:329&#x2013;334. doi:10.1007/BF02043487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02043487</ArticleId><ArticleId IdType="pubmed">6315634</ArticleId></ArticleIdList></Reference><Reference><Citation>Kon Y, Takahashi S, Takahata N, Onodera I, Sato M. 1974. Case of chronic encephalitis with Coxsackie A5 virus isolated from the cerebrospinal fluid. Rinsho Shinkeigaku 14:752&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pubmed">4477054</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zhou J, Xie G, Zheng S, Lou B, Chen Y, Wu Y. 2020. The epidemiological and clinical characteristics of hand, foot, and mouth disease in Hangzhou, China, 2016 to 2018. Clin Pediatr 59:656&#x2013;662. doi:10.1177/0009922820910822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0009922820910822</ArticleId><ArticleId IdType="pubmed">32146823</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY. 2007. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998&#x2013;2005. Pediatrics 120:e244&#x2013;e252. doi:10.1542/peds.2006-3331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2006-3331</ArticleId><ArticleId IdType="pubmed">17671037</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Yeo A, Phoon MC, Tan EL, Poh CL, Quak SH, Chow VT. 2010. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 14:e1076&#x2013;e1081. doi:10.1016/j.ijid.2010.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.07.006</ArticleId><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang CY, Liu CC. 2018. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease. Expert Rev Vaccines 17:819&#x2013;831. doi:10.1080/14760584.2018.1510326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1510326</ArticleId><ArticleId IdType="pubmed">30095317</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih C, Liao CC, Chang YS, Wu SY, Chang CS, Liou AT. 2018. Immunocompetent and immunodeficient mouse models for enterovirus 71 pathogenesis and therapy. Viruses 10:674. doi:10.3390/v10120674.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10120674</ArticleId><ArticleId IdType="pmc">PMC6316343</ArticleId><ArticleId IdType="pubmed">30487421</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Yu CK. 2014. Animal models of enterovirus 71 infection: applications and limitations. J Biomed Sci 21:31. doi:10.1186/1423-0127-21-31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1423-0127-21-31</ArticleId><ArticleId IdType="pmc">PMC4013435</ArticleId><ArticleId IdType="pubmed">24742252</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. 2002. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26:91&#x2013;107. doi:10.1111/j.1574-6976.2002.tb00601.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, Ng JK, Chow VT, Alonso S. 2012. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J Virol 86:2121&#x2013;2131. doi:10.1128/JVI.06103-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06103-11</ArticleId><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Chuang H, Yang KD. 2009. Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells. Virol J 6:141. doi:10.1186/1743-422X-6-141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-6-141</ArticleId><ArticleId IdType="pmc">PMC2751754</ArticleId><ArticleId IdType="pubmed">19751532</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Dong W, Quan X, Ma C, Qin C, Zhang L. 2012. Transgenic expression of human p-selectin glycoprotein ligand-1 is not sufficient for enterovirus 71 infection in mice. Arch Virol 157:539&#x2013;543. doi:10.1007/s00705-011-1198-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-011-1198-2</ArticleId><ArticleId IdType="pubmed">22187102</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Dai W, Zhang C, Zhou Y, Xiong P, Wang S, Ye X, Liu Q, Zhou D, Huang Z. 2018. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect 7:94. doi:10.1038/s41426-018-0094-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0094-1</ArticleId><ArticleId IdType="pmc">PMC5959873</ArticleId><ArticleId IdType="pubmed">29777102</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Ku Z, Liu Q, Leng Q, Huang Z. 2014. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine 32:2406&#x2013;2412. doi:10.1016/j.vaccine.2014.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.03.012</ArticleId><ArticleId IdType="pubmed">24657161</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Dong Z, Wei Q, Carr MJ, Li J, Ding S, Tong Y, Li D, Shi WF. 2017. A neonatal murine model of coxsackievirus A6 infection for evaluation of antiviral and vaccine efficacy. J Virol 91:e02450. doi:10.1128/JVI.02450-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02450-16</ArticleId><ArticleId IdType="pmc">PMC5391469</ArticleId><ArticleId IdType="pubmed">28250116</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Mao Q, Li S, Gao F, Zhao H, Liu Y, Wan J, Ye X, Xia N, Cheng T, Liang Z. 2016. A neonatal mouse model for the evaluation of antibodies and vaccines against coxsackievirus A6. Antiviral Res 134:50&#x2013;57. doi:10.1016/j.antiviral.2016.08.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.08.025</ArticleId><ArticleId IdType="pubmed">27582066</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C, Liu Q, Zhou Y, Ku Z, Wang L, Lan K, Ye X, Huang Z. 2016. Inactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge. Vaccine 34:5005&#x2013;5012. doi:10.1016/j.vaccine.2016.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.08.033</ArticleId><ArticleId IdType="pubmed">27562093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Dong Z, Li J, Carr MJ, Zhuang D, Wang J, Zhang Y, Ding S, Tong Y, Li D, Shi W. 2017. Protective efficacies of formaldehyde-inactivated whole-virus vaccine and antivirals in a murine model of coxsackievirus A10 infection. J Virol 91:e00333. doi:10.1128/JVI.00333-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00333-17</ArticleId><ArticleId IdType="pmc">PMC5469256</ArticleId><ArticleId IdType="pubmed">28424287</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Dong Z, Wang Q, Carr MJ, Li J, Liu T, Li D, Shi WF. 2018. Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice. Vaccine 36:7095&#x2013;7104. doi:10.1016/j.vaccine.2018.09.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.069</ArticleId><ArticleId IdType="pubmed">30316529</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Zhang X, Carr MJ, Zhou H, Li J, Liu S, Liu T, Xing W, Shi WF. 2019. A neonatal murine model of coxsackievirus A4 infection for evaluation of vaccines and antiviral drugs. Emerg Microbes Infect 8:1445&#x2013;1455. doi:10.1080/22221751.2019.1673135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2019.1673135</ArticleId><ArticleId IdType="pmc">PMC6792045</ArticleId><ArticleId IdType="pubmed">31595827</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiegers KJ, Yamaguchi-Koll U, Drzeniek R. 1977. Differences in the physical properties of dense and standard poliovirus particles. J Gen Virol 34:465&#x2013;473. doi:10.1099/0022-1317-34-3-465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-34-3-465</ArticleId><ArticleId IdType="pubmed">192836</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi-Koll U, Wiegers KJ, Drzeniek R. 1975. Isolation and characterization of &#x201c;dense particles&#x201d; from poliovirus-infected HeLa cells. J Gen Virol 26:307&#x2013;319. doi:10.1099/0022-1317-26-3-307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-26-3-307</ArticleId><ArticleId IdType="pubmed">164520</ArticleId></ArticleIdList></Reference><Reference><Citation>Wetz K, Zeichhardt H, Willingmann P, Habermehl KO. 1983. Dense particles and slow sedimenting particles produced by ultraviolet irradiation of poliovirus. J Gen Virol 64:1263&#x2013;1275. doi:10.1099/0022-1317-64-6-1263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-64-6-1263</ArticleId><ArticleId IdType="pubmed">6304233</ArticleId></ArticleIdList></Reference><Reference><Citation>Boublik M, Drzeniek R. 1976. Demonstration of a core in poliovirus particles by electron microscopy. J Gen Virol 31:447&#x2013;449. doi:10.1099/0022-1317-31-3-447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-31-3-447</ArticleId><ArticleId IdType="pubmed">180251</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiegers KJ, Yamaguchi-Koll U, Drzeniek R. 1976. A complex between poliovirus RNA and the structural polypeptide VP1. Biochem Biophys Res Commun 71:1308&#x2013;1312. doi:10.1016/0006-291x(76)90797-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-291x(76)90797-x</ArticleId><ArticleId IdType="pubmed">184788</ArticleId></ArticleIdList></Reference><Reference><Citation>He M, Xu L, Zheng Q, Zhu R, Yin Z, Zha Z, Lin Y, Yang L, Huang Y, Ye X, Li S, Hou W, Wu Y, Han J, Liu D, Li Z, Chen Z, Yu H, Que Y, Wang Y, Yan X, Zhang J, Gu Y, Zhou ZH, Cheng T, Li S, Xia N. 2020. Identification of antibodies with non-overlapping neutralization sites that target coxsackievirus A16. Cell Host Microbe 27:1&#x2013;13. doi:10.1016/j.chom.2020.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.01.003</ArticleId><ArticleId IdType="pmc">PMC7539366</ArticleId><ArticleId IdType="pubmed">32027857</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, Sun D, Guo J, Elgner F, Wang M, Hildt E, Cheng A. 2019. Multifunctionality of structural proteins in the enterovirus life cycle. Future Microbiol 14:1147&#x2013;1157. doi:10.2217/fmb-2019-0127.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb-2019-0127</ArticleId><ArticleId IdType="pubmed">31368347</ArticleId></ArticleIdList></Reference><Reference><Citation>Standardization Administration of China. 2018. Laboratory animal&#x2014;guideline for ethical review of animal welfare. Standardization Administration of China, Beijing, China.</Citation></Reference><Reference><Citation>Hankaniemi MM, Laitinen OH, Stone VM, Sioofy-Khojine A, M&#xe4;&#xe4;tt&#xe4; JAE, Larsson PG, Marjom&#xe4;ki V, Hy&#xf6;ty H, Flodstr&#xf6;m-Tullberg M, Hyt&#xf6;nen VP. 2017. Optimized production and purification of coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model. Vaccine 35:3718&#x2013;3725. doi:10.1016/j.vaccine.2017.05.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.05.057</ArticleId><ArticleId IdType="pubmed">28579231</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin WP, Lu J, Wu J, Hu G, Zhou JG, Wang WH, Wang ZJ, Meng SL, Shen S. 2020. Prokaryotic expression and polyclonal antibody preparation of coxsackievirus A5 VP1. Int J Biol 43:53&#x2013;57. doi:10.3760/cma.j.cn311962-20191118-00063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn311962-20191118-00063</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu YX, Guo JY, Shen L, Chen Y, Zhang ZC, Zhang YL. 2002. Get effective polyclonal antisera in one month. Cell Res 12:157&#x2013;160. doi:10.1038/sj.cr.7290122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cr.7290122</ArticleId><ArticleId IdType="pubmed">12118942</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>